Specifically, increased type I interferon signaling reduces immunosuppression in the tumor microenvironment by upregulating CD45+ immune cells, CD8+ T‐cells, and natural killer cells, and is associated with favorable outcomes [45, 63, 64]. Here, PTPRC is linked to neoplasm.